Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Purvi Parikh

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Advances in Therapy|October 6, 2025
The Global Patient Perspective on Uncontrolled Moderate-to-Severe Asthma: Reducing Delays in Diagnosis and TreatmentKaren Rance, Brenda Young, Gretchen McCreary, et al.
Archives of Surgery (Chicago, Ill. : 1960)|July 21, 2010
Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experienceC Max Schmidt, Olivier Turrini, Purvi Parikh, et al.
Frontiers in Immunology|July 15, 2021
Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine LearningBruce K Patterson, Jose Guevara-Coto, Ram Yogendra, et al.
Frontiers in Medicine|May 30, 2024
Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)Bruce K Patterson, Ram Yogendra, Jose Guevara-Coto, et al.
Frontiers in Medicine|February 27, 2023
Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC)Bruce K Patterson, Ram Yogendra, Jose Guevara-Coto, et al.
Frontiers in Immunology|January 27, 2022
Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-InfectionBruce K Patterson, Edgar B Francisco, Ram Yogendra, et al.
Frontiers in Immunology|May 11, 2026
Correction: Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infectionBruce K Patterson, Edgar B Francisco, Ram Yogendra, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Advances in Therapy|October 6, 2025
The Global Patient Perspective on Uncontrolled Moderate-to-Severe Asthma: Reducing Delays in Diagnosis and TreatmentKaren Rance, Brenda Young, Gretchen McCreary, et al.
Archives of Surgery (Chicago, Ill. : 1960)|July 21, 2010
Effect of hospital volume, surgeon experience, and surgeon volume on patient outcomes after pancreaticoduodenectomy: a single-institution experienceC Max Schmidt, Olivier Turrini, Purvi Parikh, et al.
Frontiers in Immunology|July 15, 2021
Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine LearningBruce K Patterson, Jose Guevara-Coto, Ram Yogendra, et al.
Frontiers in Medicine|May 30, 2024
Corrigendum: Case Series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequalae of COVID (PASC)Bruce K Patterson, Ram Yogendra, Jose Guevara-Coto, et al.
Frontiers in Medicine|February 27, 2023
Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC)Bruce K Patterson, Ram Yogendra, Jose Guevara-Coto, et al.
Frontiers in Immunology|January 27, 2022
Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-InfectionBruce K Patterson, Edgar B Francisco, Ram Yogendra, et al.
Frontiers in Immunology|May 11, 2026
Correction: Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infectionBruce K Patterson, Edgar B Francisco, Ram Yogendra, et al.
Pageof 2